Active substances
Azelastine + Fluticasone
- SFDA 1
- US FDA 4
- Health Canada 3
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DYMISTA | 1000,365 µg,µg | Nasal spray, suspension · Inhalation use | 1 Bottle | SAR 77.20 | NCE · Prescription | Viatris Healthcare GmbH | Valid |
Indications — CHI Daman Drug Formulary
ALLERGIC RHINITIS; ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DYMISTA | 0.137MG/SPRAY;0.05MG/SPRAY | spray, metered · nasal | MYLAN SPECIALITY LP | Prescription | 1 May 2012 |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | 0.137MG/SPRAY;0.05MG/SPRAY | spray, metered · nasal | APOTEX | Prescription | 28 Apr 2017 |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | 0.137MG/SPRAY;0.05MG/SPRAY | spray, metered · nasal | PADAGIS ISRAEL | Prescription | 18 Feb 2021 |
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | 0.137MG/SPRAY;0.05MG/SPRAY | spray, metered · nasal | TEVA PHARMS USA INC | Prescription | 8 Apr 2025 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-AZELASTINE/FLUTICASONE | 02540886 | 50 MCG / ACT; 137 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | APOTEX INC |
| DYMISTA | 02432889 | 50 MCG / ACT; 137 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | BGP PHARMA ULC |
| MYLAN-AZELASTINE/FLUTICASONE | 02530341 | 50 MCG / ACT; 137 MCG / ACT | SPRAY (METERED-DOSE) · NASAL | MYLAN PHARMACEUTICALS ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray | £3.84 | 120 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.